Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1998-01-22
2000-11-14
Woodward, Michael P.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241301, 4241411, 4241331, 4241421, 4241611, 435 7021, 435326, 435339, A61K 3942, A61K 39395, C12N 506, C12N 516
Patent
active
061466298
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention concerns a hybridoma cell line producing human antibodies capable of binding to the hepatitis B virus surface antigen, antibodies produced by the cell lines, and various uses thereof.
BACKGROUND OF THE INVENTION
Hepatitis B virus (HBV) infection is a major worldwide health problem. Approximately 5% of the world population is infected by HBV and chronically infected patients carry a high risk of developing cirrhosis and hepatocellular carcinoma. (Progressive Hepatitis Research: Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Hepatitis Delta virus (HDV) Ed. O. Crivelli, Sorina Biomedica, 1991).
The immune response to HBV-encoded antigens includes both a cellular immune response which is active in the elimination of HBV infected cells, as well as a humoral antibody response to viral envelope antigens which contributes to the clearance of circulating virus particles. The dominant cause of viral persistence during HBV infection is the development of a weak antiviral immune response.
Recombinant HBV vaccines provide a safe and effective means for active immunization against HBV, however, they do not always induce a sufficient and rapid antibody response.
Interferon-.alpha. has been used in the therapy of Hepatitis B infection showing an efficacy of only 30-40% in highly selected patients.
In addition, passive immunization with human polyclonal anti Hepatitis B antisera has been shown to be effective in delaying and even preventing recurrent HBV infection (Wright, T. L. and Lau, J. Y. N. The Lancet 342:1340-1344, (1993)). Such human polyclonal antisera are prepared from pooled plasma of immunized donors. These preparations are very expensive and available in relatively small amounts. Furthermore, pooled plasma may contain contaminated blood samples and thus treatment with such antisera increases the patient's risk to contract other viral infections such as hepatitis C or HIV.
An alternative approach for the treatment of HBV infections concerns the use of monoclonal antibodies (MoAb).
PCT patent application PCT/NL94/00102 discloses human monoclonal antibodies directed against Hepatitis B surface antigen which are secreted by the hybridoma cell lines Mab 4-7B and Mab 9H9. The monoclonal antibody secreted by the cell line Mab 4-7B recognizes a linear epitope of HBVsAg and is different from the Mab 9H9 monoclonal antibody which recognizes a conformational epitope. The antibodies are claimed for simultaneous use in the treatment of chronic Hepatitis B infections.
PCT patent application PCT/US92/09749 discloses human monoclonal antibodies against HBVsAg which are secreted by the hybridoma cell lines PE1-1, ZM1-1, ZM1-2, MD3-4 and LO3-3. The antibodies bind to different HBV epitopes and are used for reducing the level of circulating HBVsAg.
Japanese Patent Application JP 93066104 discloses a hybridoma of a human lymphocyte cell strain TAW-925 and a human lymphocyte transformed by Epstein-Barr virus. The hybridoma produces a human monoclonal antibody against HBVsAg.
U.S. patent application Ser. No. 4,883,752 discloses preparation of human-derived monoclonal antibody to HBVsAg, by administration of HBVsAg vaccine to humans, recovering their lymphocytes, stimulating the lymphocytes in vitro by a non specific stimulator, fusing said cells with a myeloma cell, and selecting for hybridomas with secrete anti HBVsAg antibodies.
Ichimori et al., Biochem. and Biophysic. Research Communications 129(1):26-33, 1985 discloses a hybridoma secreting human anti HBVsAg monoclonal antibodies which recognize the a-determinant of HBVsAg. Later, Ichimori, et al., supra 142(3):805-812, 1987 disclosed another hybridoma which stably secretes human monoclonal antibody against HBsAg.
SUMMARY OF THE INVENTION
In accordance with the present invention, a hybridoma cell line is provided which secretes human antibodies capable of binding to the Hepatitis B surface antigen (HBVsAg).
In accordance with the invention, peripheral blood lymphocytes (PBL) were obtained from human individuals having a
REFERENCES:
patent: 4714613 (1987-12-01), Shouval
patent: 4778761 (1988-10-01), Miyanohara
patent: 4883752 (1989-11-01), Eda
patent: 5223263 (1993-06-01), Hostetler
patent: 5565354 (1996-10-01), Ostberg
patent: 5648077 (1997-07-01), Ostberg
Ehrlich et al. 1992 Human Antibodies and Hybridomas vol. 3 p 2-7, Jan. 1992.
Ehrlich et al. Hum. Antibod. Hybridomas 3: 2-7, 1992.
Woodward Michael P.
XTL Biopharmaceuticals Limited
Zeman Mary K
LandOfFree
Human monoclonal antibody against Hepatitis B virus surface anti does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibody against Hepatitis B virus surface anti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibody against Hepatitis B virus surface anti will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062307